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Uterine cervical and endometrial cancers are common malignant solid neoplasms for which there are no useful prognostic markers. In
this study, we evaluate the relationship between ATP-binding cassette superfamily F2 (ABCF2) expression and clinical factors
including clinical stage, histologic type, grade and prognosis in uterine cervical and endometrial cancer. Two hundred and sixty seven
cervical and 103 endometrial cancers were studied. ATP-binding cassette superfamily F2 cytoplasmic expression was detected by
immunohistochemical staining and scored as positive or negative. Among cervical cancer cases, 149 (55.8%) expressed ABCF2. The
overall survival was longer in ABCF2-negative than ABCF2-positive cases (P¼0.0069). Statistically significant prognostic factors for
survival were ABCF2 positivity (risk ratio (rr)¼1.437), old age (rr¼1.550) and advanced stage (rr¼2.577). ATP-binding cassette
superfamily F2 positivity was an independent prognostic factor by multivariate proportional hazard test (P¼0.0002). Among
endometrial cancer cases, 72 (69.9%) were cytoplasmic ABCF2 positive. However, there was no significant relationship between
ABCF2 expression and age, clinical stage, histologic type, histologic grade, oestrogen receptor status or prognosis. ATP-binding
cassette superfamily F2 expression may be a useful prognostic marker in cervical but not endometrial cancer. The role of ABCF2
protein may differ depending on the type of cancer.
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Carcinoma of the uterine cervix is a common malignant solid
neoplasm in Japanese women and its incidence in young women is
increasing (Ioka et al, 2003; The Japan Cancer Surveillance
Research Group, in press). The prognosis is influenced by health
condition such as anaemia, hypertension, neutrophil count or
diabetes, clinical stage including tumour volume, endometrial
extension and lymph node involvement (Stehman et al, 2000).
Several studies have assessed the role of human papillomavirus
(HPV) and HPV type on outcome with conflicting results (Randall
et al, 2005). Proliferation, apoptosis and other cellular character-
istics have been suggested to correlate with clinical outcome
although these associations have not been conclusively established
(Riou et al, 1988; Sagae et al, 1989; Koulos et al, 1993; Tsang et al,
1995; Gaffney et al, 2003). Several genes that control cell growth
and differentiation have been investigated as prognostic markers
in cervical cancer, but as yet no clearly useful marker has been
identified.
Endometrial cancer is also increasing in Japan (Ioka et al, 2003;
The Japan Cancer Surveillance Research Group, in press) and the
prognosis is reported to be influenced by histologic type, grade and
clinical stage (Trope et al, 2005). Mutations of p53 gene, HER-2/
neu amplification and reduced E-cadherin expression have been
reported to be poor prognostic indicators but their importance
remains to be established (Hamel et al, 1996; Lundgren et al, 2002;
Moreno-Bueno et al, 2002). New biomarkers able to predict the
prognosis of uterine cervical and endometrial cancers are therefore
urgently needed and would be extremely useful.
We have produced an antibody to the ATP-binding cassette
superfamily F (ABCF2) protein and demonstrated that ABCF2
protein expression is higher in clear cell adenocarcinoma (CCC) of
the ovary than in other histologic types and may predict
chemotherapy response and prognosis (Tsuda et al, 2005a;
Nishimura et al, 2007). ATP-binding cassette superfamily F2 is a
member of the GCN20 subfamily of the ABC transporter super-
family (Vasquez de Aldana et al, 1995; Allikmets et al, 1996; Kerr,
2004). Yasui et al reported that the ABCF2 gene is amplified in a
chemoresistant ovarian cancer cell line (t24/cDDp10), with
chromosome gain at 7q34–36 (Yasui et al, 2005). In this study,
we evaluate the relationship between ABCF2 expression and
clinical stage, histologic type, histologic grade and prognosis in
uterine cervical and endometrial cancer.
MATERIALS AND METHODS
Clinical samples
Between February 1994 and December 2004, 385 samples (267
invasive cervical cancers, 103 endometrial cancer, 5 proliferative
endometrium, 5 secretary phase endometrium and 5 normal
cervical epithelium) of paraffin-embedded tissues were collected at
Osaka City General Hospital. All patient-derived paraffin sections
were archived under the protocols approved by the institutional
review board (IRB) of Osaka City General Hospital. Revised 13 August 2008; accepted 23 September 2008
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sOf 267 invasive cervical cancers, 146 were stage I, 67 stage II, 33
stage III and 21 stage IV. Two hundred and twenty six were
squamous cell carcinoma, 26 adenocarcinoma and 15 adenosqua-
mous cell carcinoma. Among the 103 endometrial cancers, 63 were
stage I, 6 stage II, 31 stage III and 3 stage IV. Eighty-six were
endometrioid adenocarcinoma, six adenoachanthoma, five adeno-
squamous carcinoma, four CCC and two undifferentiated carci-
noma. Forty-four were grade1, 42 grade 2 and 13 grade 3. The
median ages of cervical and endometrial cancer patients were 53
(range 22–92) and 55 years (range 32–77), respectively. Histologic
diagnosis was confirmed by microscopic examination of hema-
toxylin-and-eosin-stained sections according to the International
Federation of Gynecology and Obstetrics (FIGO) system.
As primary therapy 70 cervical cancer patients received
radiation therapy and 197 surgery. After primary therapy, 55 had
adjuvant radiotherapy and 10 platinum based adjuvant chemo-
therapy. Twenty-nine patients received platinum-based neoadju-
vant chemotherapy. All endometrial cancer patients were first
treated surgerically. Post-operatively 51 received platinum-based
adjuvant chemotherapy and 2 adjuvant radiotherapy.
Immunohistochemistry
ATP-binding cassette superfamily F2 protein expression was
detected immunohistochemically using a polyclonal anti-ABCF2
antibody generated by immunising rabbits with a purified full-
length ABCF2 fusion protein. The specificity of the antibody was
determined by western blot and immunohistochemical analyses
on human embryonic kidney cells (293T) transfected with an
AB
C
Figure 1 (A) ATP-binding cassette superfamily F2-positive proliferative endometrium. (B) ATP-binding cassette superfamily F2-positive secretary
endometrium. (C) ATP-binding cassette superfamily F2-negative cervical epithelium.
Table 1 ATP-binding cassette superfamily F2 (ABCF2) expression in
cervical cancer
Parameter ABCF2 expression P-value
Age
oMedian 50.4% (71/141) 0.065
4Median 61.9% (78/126)
FIGO stage
I+II 50.7% (108/213) 0.001
III+IV 75.9% (41/54)
Histologic type
Squamous 54.9% (124/226) 0.499
Non-squamous 61.0% (25/41)
Table 2 ATP-binding cassette superfamily F2 (ABCF2) expression in
endometrial cancer
Parameter ABCF2 expression P-value
Age
oMedian 68.6% (35/51) 0.832
4Median 71.2% (37/52)
FIGO stage
I+II 68.1% (47/69) 0.652
III+IV 73.5% (25/34)
Histologic type
Endometrioid 69.6% (64/92) 0.999
Non-endometrioid 72.7% (8/11)
Histologic grade
1+2 68.6% (59/86) 0.773
3 76.5% (13/17)
Estrogen receptor
Positive 71.2% (47/66) 0.384
Negative 58.8% (10/17)
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sexpression vector pcDNA3.1 or with the vector containing
either a full-length ABCF2 coding sequence or a full-length
ABCF2 coding sequence with a myc and a His tag (Tsuda et al,
2005b).
Histological sections (4mm) were affixed to glass slides, dewaxed
and rehydrated. The sections were incubated in 3% hydrogen
peroxide for 10min at room temperature to quench endogeneous
peroxidase activity and incubated with the ABCF2 antibody
(1:5000) at 41C overnight. After rinsing, the sections were
incubated for 30min with rabbit EnVisionþ Peroxidase (DAKO,
Glostrup, Denmark). Peroxidase activity was visualised by apply-
ing diaminobenzidine chromogen containing 0.05% hydrogen
peroxide for 2–10min at room temperature, and the sections were
counterstained with hematoxylin. Slides were read by two
independent pathologists, who were blinded to the clinical
background of the patients. Evaluation of ABCF2 positives were
reported previously (Tsuda et al, 2005a; Nishimura et al, 2007).
ATP-binding cassette superfamily F2 protein is a member of ABC
transporter superfamily and the GCN20 subfamily (Vasquez de
Aldana et al, 1995) and we demonstrated that ABCF2 protein is
predominantly located in the cytoplasm of cells (Tsuda et al,
2005a; Nishimura et al, 2007). Thus, in this study, we judged the
positivities of this protein based on the cytoplasmic staining into
either positive or negative.
Slides from epithelial ovarian cancer patients confirmed to be
ABCF2 positive or negative in previous reports that were used as
controls (Tsuda et al, 2005a; Nishimura et al, 2007).
Statistical analysis
The relationship between ABCF2 expression and age, clinical stage
and histologic type were analysed by w
2 test. Patients were
categorised as young or old (453 years) and early or advanced
(not less than stage IIIa) disease. Factors influencing 5-year survival
were analysed by both Cox’s proportional hazard test and the
Kaplan–Meier test. After investigation of the multicollinearity of
these factors, multivariate Cox’s proportional hazard test was
applied. A P-value of o0.05 was considered statistically significant.
RESULTS
ABCF2 expression
In one of seven proliferative endometriums and six of eight
secretary endometriums, ABCF2 cytoplasmic weakly immuno-
staining was detected; however, in normal cervical epithelium, no
ABCF2 immunostaining was detected (Figure 1A–C). Among
AB
CD
EF
Figure 2 ATP-binding cassette superfamily F2 immunohistochemical staining in cervical and endometrial cancer. (A) ATP-binding cassette superfamily
F2-positive cervical cancer (squamous cell carcinoma). (B) ATP-binding cassette superfamily F2-negative cervical cancer (squamous cell carcinoma).
(C) ATP-binding cassette superfamily F2-positive cervical cancer (adenocarcinoma). (D) ATP-binding cassette superfamily F2-negative cervical cancer
(adenocarcinoma). (E) ATP-binding cassette superfamily F2-positive endometrial cancer. (F) ATP-binding cassette superfamily F2-negative endometrial
cancer.
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scervical cancer cases, 149 (55.8%) were cytoplasmic ABCF2
positive. ATP-binding cassette superfamily F2 was more frequently
expressed in advanced (stage IIIþIV) than in early (stage IþII)
cases (75.9 vs 50.7%, P¼0.001). However, there was no significant
relationship between age, histologic type and ABCF2 expression
(Table 1). Among endometrial cancer cases, 72 (69.9%) were
cytoplasmic ABCF2 positive. There was no association between
age, clinical stage, histologic type, histologic grade, oestrogen
receptor status and ABCF2 expression (Table 2). Representative
ABCF2 staining is shown in Figure 2.
Relationship between ABCF2 expression and overall
survival (OS)
The median follow-up period for cervical cancer patients was 1280
days (20–4679 days). Overall survival was significantly related to
age and clinical stage but not to histologic type. The OS was longer
in stage IþII than in stage IIIþIV cases (Po0.0001) and in
younger than older cases (P¼0.0007). Twenty of 118 ABCF2
negative and 41 of 149 ABCF2-positive cases died. Overall survival
of ABCF2 negative was longer than ABCF2-positive cases
(P¼0.0069) (Figure 3A). Prognostic factors influencing survival
were ABCF2 positivity (risk ratio (rr)¼1.437; Ph¼0.0063 by
proportional hazard test, Pl¼0.0069 by log-rank and Pw¼0.001 by
Wilcoxon test), old age (rr¼1.550; Ph¼0.0008, Pl¼0.0007 and
Pw¼0.0015) and advanced stage (rr¼2.577; Pho0.0001,
Plo0.0001 and Pwo0.0001) (Table 3). ATP-binding cassette
superfamily F2 positivity and old age were independent significant
prognostic factors by multivariate proportional hazard test
(P¼0.0002). The rrs for negative ABCF2 and old age were 0.720
(0.544–0.936; 95% CI, P¼0.00137) and 1.510 (1.167–1.978,
P¼0.0016), respectively.
For endometrial cancer cases the median follow up period was
1429 days (93–3675 days). Overall survival was longer in stage
IþII disease than in stage IIIþIV cases (Po0.0001). Endo-
metrioid adenocarcinoma had better OS than non-endometrioid
adenocarcinoma (P¼0.001). However, there was no relationship
between ABCF2 expression and OS (P¼0.67) (Figure 3B).
DISCUSSION
Recently, we reported that ABCF2 expression was related to
prognosis in ovarian CCC and breast cancer. In ovarian CCC,
ABCF2 expression was associated with chemoresistance and OS
(Tsuda et al, 2005a,b; Ogawa et al, 2006), while in breast cancer,
lack of ABCF2 expression was associated with increased disease-
free survival (Ogawa et al, 2006). ATP-binding cassette superfamily
F2 is a member of the GCN20 subfamily of the ABC transporter
superfamily (Vasquez de Aldana et al, 1995). Similar to other
members of the ABC family, ABCF2 contains a pair of nucleotide-
binding domains but it lacks a transmembrane domain (Allikmets
et al, 1996; Kerr, 2004), suggesting that it is unlikely to function as
a cell membrane transporter, as do other members of the ABC
family. ATP-binding cassette superfamily F2 may be involved in
translational control, antibiotic resistance and RNase L inhibition
(Trope et al, 2005). Although the ABCF2 gene is amplified in a
chemoresistant ovarian cancer cell line (t24/cDDp10) with
chromosome gain at 7q34–36 (Yasui et al, 2005), its role in
tumour biology remains to be established. In this study, we
examined the relationship between ABCF2 expression, clinical
factors and prognosis in cervical and endometrial cancer.
In cervical cancer, ABCF2 expression was higher in stages III
and IV than stages I and II tumours but expression was not related
to histology or age of the patients. The OS was longer in ABCF2-
negative than ABCF2-positive cases (P¼0.0069). In addition,
ABCF2 positivity was shown to be a significant independent
prognostic factor by multivariate proportional hazard test. In
cervical cancer, squamous cell antigen (SCC) is thought to be a
useful marker. Pretreatment SCC levels correlate with cellular
differentiation, tumour stage and volume, lymph node status and
blood vessel invasion (Reynolds et al, 2005). However, there are
conflicting reports on the prognostic significance of pretreatment
SCC measurements (Scambia et al, 1994; Gaarenstroom et al, 1995;
Duk et al, 1996; Ngan et al, 1996; Bolger et al, 1997; Hong et al
1998). In addition, there are no useful markers in cervical
adenocarcinoma. In this study, the ABCF2 positivity rate was
61% (25 of 41) in cervical non-squamous cell carcinoma and
expression correlated with OS. ATP-binding cassette superfamily
F2 may therefore be a useful biomarker in cervical cancer,
although a larger study will be needed to confirm this conclusion.
In contrast, ABCF2 expression was not related to OS and clinical
factors such as age, stage, histologic type, histologic grade and
oestrogen receptor status in endometrial cancer. Thus, the role of
ABCF2 may differ according to tumour type.
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Figure 3 (A) Relationship between ABCF2 expression and OS in
cervical cancer. ATP-binding cassette superfamily F2-negative cases show
longer OS than in ABCF2-positive cases (P¼0.0069). (B) Relationship
between ABCF2 expression and the OS in endometrial cancer. ATP-
binding cassette superfamily F2 expression and OS are not related
(P¼0.67).
Table 3 Statistical analysis of prognostic factors for OS
Variable
Univariate
P-value
Hazard
ratio 95% CI
Age 0.0008 1.549 1.199–2.029
Histology 0.17 1.242 0.904–1.651
Clinical stage o0.0001 2.577 1.993–3.329
ABCF2 0.0063 0.696 0.527–0.904
Age: 4median age, histology: non-squamous cell carcinoma. Clinical stage: III+IV,
ABCF2: negative. Hazard ratio refers to risk of death, with values o1.0 indicating
reduced risk. CI¼confidence interval.
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with histologic types (significantly higher in clear-cell type
compared with other histologic types) (Tsuda et al, 2005a;
Nishimura et al, 2007). However, in cervical and endometrial
cancer, its expression was not related with histologic types. In
cervical cancer and clear cell types of ovarian cancer, ABCF2
expression was related with survival, however, in endometrial
cancer and other histologic types of ovarian cancer, its expression
was not related with survival (Tsuda et al, 2005b). The reason
remains unclear. The role of ABCF2 protein may differ among
histologic types or origin.
In conclusion, ABCF2 expression may be a useful
prognostic marker in cervical cancer but its expression
is not related to prognosis and clinical factors in endometrial
cancer.
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